Fox Run Management L.L.C. bought a new position in InVitae Corp (NASDAQ:NVTA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 33,300 shares of the medical research company’s stock, valued at approximately $312,000. Fox Run Management L.L.C. owned approximately 0.08% of InVitae Corp at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. CAPROCK Group Inc. purchased a new position in shares of InVitae Corp in the third quarter worth approximately $139,000. California State Teachers Retirement System grew its position in InVitae Corp by 24.1% during the second quarter. California State Teachers Retirement System now owns 69,009 shares of the medical research company’s stock valued at $660,000 after purchasing an additional 13,400 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in InVitae Corp by 34.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,129 shares of the medical research company’s stock valued at $307,000 after purchasing an additional 8,244 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in InVitae Corp during the second quarter valued at approximately $202,000. Finally, State Street Corp grew its position in InVitae Corp by 43.1% during the second quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock valued at $5,528,000 after purchasing an additional 174,016 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/fox-run-management-l-l-c-takes-312000-position-in-invitae-corp-nvta/1677668.html.

InVitae Corp (NVTA) opened at $8.31 on Friday.

InVitae Corp (NASDAQ:NVTA) last announced its quarterly earnings data on Monday, November 6th. The medical research company reported ($0.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.37). InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%.

A number of research analysts recently commented on the stock. BidaskClub downgraded shares of InVitae Corp from a “hold” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research downgraded shares of InVitae Corp from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $15.00 price objective (up from $14.00) on shares of InVitae Corp in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. InVitae Corp presently has a consensus rating of “Hold” and an average price target of $13.50.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.